MedTrace Logo

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

NCT04901806 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-03-28

No results posted yet for this study

Summary

This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.

Conditions

  • Solid Tumor, Adult
  • Brain Tumor, Primary
  • Desmoplastic Small Round Cell Tumor

Interventions

DRUG

PBI-200

PBI-200 will be administered orally over continuous 28-day cycles

Sponsors & Collaborators

  • Pyramid Biosciences

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Pyramid Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2023-07-26
Completion
2023-07-26
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • France
  • Germany
  • Hong Kong
  • Italy
  • Singapore
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901806 on ClinicalTrials.gov